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Genetic engineering of T cells with chimeric T-cell receptors (CARs) is an attractive strategy to treat malignancies. It extends the
range of antigens for adoptive T-cell immunotherapy, and major mechanisms of tumor escape are bypassed. With this strategy we
redirected immune responses towards the CD33 antigen to target acute myeloid leukemia. To improve in vivo T-cell persistence,
we modiﬁed human Epstein Barr Virus-(EBV-) speciﬁc cytotoxic T cells with an anti-CD33.CAR. Genetically modiﬁed T cells
displayed EBV and HLA-unrestricted CD33 bispeciﬁcity in vitro. In addition, though showing a myeloablative activity, they
did not irreversibly impair the clonogenic potential of normal CD34+ hematopoietic progenitors. Moreover, after intravenous
administration into CD33+ human acute myeloid leukemia-bearing NOD-SCID mice, anti-CD33-EBV-speciﬁc T cells reached the
tumor sites exerting antitumor activity in vivo. In conclusion, targeting CD33 by CAR-modiﬁed EBV-speciﬁc T cells may provide
additional therapeutic beneﬁt to AML patients as compared to conventional chemotherapy or transplantation regimens alone.
1.Introduction
Eﬀorts to circumvent the limitations and improve the antitu-
moreﬃcacyofcurrentadoptiveimmunotherapyapproaches
have led to the development of novel strategies that combine
the advantages of a T-cell-based therapy (tumor penetration,
immune eﬀector functions) and of antibody-based strategy
(high speciﬁcity towards target antigen). The observation
that engagement of a single T-cell receptor (TCRs) chain can
induce cellular activation led to the design of chimeric an-
tigen receptors (CAR), combining in a single molecule the
antigen recognition (through motifs derived from single
chain, highly variable antibody fragments, scFv) with signal
transduction and activation motives (usually the TCR-ζ
chain motif, CD3-ζ). CAR can be generated against every
identiﬁed tumor-associated antigen (TAA) for which an
antibodyexists,includingcarbohydratesandglycolipids.The
genetic modiﬁcation of T cells to express CAR can redirect
them toward tumor cells in a non-HLA-restricted manner.
Nevertheless, the in vivo eﬃcacy of CAR-expressing T cells
is limited because the engagement of the CAR alone is
usually not suﬃcient to mediate the critical costimulatory
signals necessary for complete activation and persistence
of genetically engineered T cells in vivo [1]. Expression
of the CAR into antigen-speciﬁc cytotoxic T cells (CTLs)
redirects the activated T cells (through their native TCR2 Advances in Hematology
and costimulatory pathways) towards their new target [2–
4]. The genetic modiﬁcation of Epstein Barr Virus-speciﬁc-
CTLs (EBV-CTLs) with tumor-speciﬁc CAR is particularly
attractive because most individuals are persistently infected
with EBV and express viral antigens in epithelial cells and B
lymphocytes [5] .T h i sa p p r o a c hh a sb e e nv a l i d a t e di ns e v e r a l
recently published clinical trials [6–8].
CD33 is a myeloid-speciﬁc sialic acid-binding receptor
overexpressed on the cell surface of 90% of acute myeloid
leukemia (AML) blasts. CD33 has a role in regulating leu-
kocyte functions in inﬂammatory and immune responses
[9]. Normal granulomonocytic progenitors and mature cells
express CD33, but not all normal hematopoietic stem cells
[10, 11]. Conversely, AML stem cells express surface CD33
[12]. Gemtuzumab ozogamicin, a humanized anti-CD33
monoclonal antibody combined with calicheamicin (a cyto-
static drug derived from anthracyclins), has demonstrated
eﬀective albeit short-lived antileukemic eﬀects in clinical tri-
als [13, 14]. Main side eﬀects described in patients receiving
this drug include myelosuppression, transient neutropenias,
thrombocytopenias, and hepatic toxicity, which are related
both to the expression of CD33 on myeloid progenitors and
on Kuppfer cells and, most importantly, to the accumulation
of free calicheamicin in the liver [13]. Contrary to other
monoclonal antibody-based strategies, escape mechanisms
towards gemtuzumab ozogamicin are not driven by down-
regulation of CD33 on tumor cells, but rather by chemore-
sistance due to the extracellular eﬄux of calicheamicin
by ATP-dependant multidrug resistance (MDR) pumps
[15, 16]. Thus, we hypothesized that an adoptive cellular
therapy approach targeting CD33+ AML cells with CD33-
speciﬁc CAR-expressing-EBV-CTLs should provide all the
beneﬁts of a T-cell-based immune eﬀect: tumor cell killing
in particular via an intrinsic antibody-dependant cellular
cytotoxic eﬀect, cytokine release, improved tumor penetra-
tion, and prolonged persistence compared to monoclonal
antibody therapy. Furthermore, it should circumvent the
chemoresistancemechanismsandthetoxicityobservedwhen
combining a chemotherapeutic agent such as calicheamicin,
with an anti-CD33 antibody, with the additional possibility
to improve its safety proﬁle, through the coexpression of a
suicide gene [17].
We recently showed that the CD33-CAR approach eﬀec-
tively enhances the antileukemic activity of cytokine induced
killer (CIK) cells [18], and, with this study, we extend our
observation to EBV-CTLs, whose eﬃcacy in the clinical
setting has been widely documented, demonstrating that
CD33-speciﬁc CAR-expressing EBV-CTLs can be redirected
towards human CD33+ AML blasts in vitro and in vivo in a
xenograft NOD-SCID mice model of AML.
2.DesignandMethods
2.1. Cell Lines. The human CD33+ myeloid leukemia cell
lines AML10 and ﬀLuc+ AML10 were generated and kind-
ly provided by Dean Lee (The University of Texas MD
Anderson Cancer Center, Houston, TX), after serial pas-
sages in vivo in NOD-SCID mice. AML10, ﬀLuc+ AML10,
and KG-1 (human CD33+ AML, ATCC, Manassas, VA)
cell lines were all maintained in RPMI (BioWhittaker,
Walkersville, MD) supplemented with 10% heat-inactivated
f e t a lc a l fs e r u m( F C S ,H y c l o n e ,L o g a n ,U T ) ,2 0 0 I U / m L
penicillin, 200μg/mL streptomycin, and 2mL glutamine
(Invitrogen, Carlsbad, CA), further referred as complete
medium. 293T cells (ATCCs) were cultured in IMDM
(Invitrogen) supplemented as indicated above. Epstein-Barr
virus B-lymphoblastoid cell lines (LCLs) were generated
from six EBV-seropositive donors. For each donor, 5-10x106
peripheral blood mononuclear cells (PBMC) were used for
the establishment of EBV-LCLs by infection of PBMC with
concentratedsupernatantsfromtheB95-8workingcellbank,
as previously described [19].
2.2. Chimeric Receptor Cloning and Retrovirus Production.
The high-aﬃnity, humanized rat anti-human CD33, 113,
in single-chain fragment variable-Fv-(L-(gly4ser)4-H gen-
erated using UCB’s Selected Lymphocyte Antibody Method
(kindly provided by Dr. Helene Finney, UCB Celltech,
Slough, UK), was cloned in frame with CH2CH3-CD28
transmembrane-ζ domain in the SFG retroviral construct
(kindly provided by Martin Pule, UCL, London, UK). Tran-
sient retroviral supernatant was produced by cotransfection
of 293T cells with the MoMuLV gag/pol expression plasmid
PeqPam3, the RD114 env expression plasmid, and the SFG-
anti-CD33-ζ vector using GeneJuice transfection reagent
(Calbiochem, San Diego, CA), according to manufacturers’
instructions. The supernatant containing the retroviruses
was harvested 2 and 3 days after transfection, snap-frozen,
a n ds t o r e da t−80◦C for further use.
2.3. Generation and Transduction of EBV-CTLs Lines. EBV-
speciﬁc T-cell lines were generated as previously reported
[20]. Brieﬂy, PBMCs (2 × 106 per well of a 24-well plate)
were stimulated with autologous LCLs irradiated at 40Gy
at an eﬀector-to-stimulator (E:S) ratio of 40:1. Starting
on day 10, the responder cells were restimulated weekly
with irradiated LCLs at an E:S ratio of 4:1, and rhIL-
2 (50U/mL) was added twice a week starting at the third
stimulation. EBV-CTLs were transduced 48 to 72 hours after
the third stimulation by irradiated autologous LCLs. CTLs
were resuspended at 1 × 106 cells/mL in complete culture
medium and were incubated with 1.5 volume of retroviral
supernatant for 48 hours at 37◦C and 5% CO2.T r a n s d u c e d
EBV-CTLs were further stimulated by weekly restimulations
with irradiated autologous LCLs in the presence of rhIL-2
(50U/mL).
2.4. Immunophenotyping. Gene-modiﬁed EBV-CTLs were
analyzed for cell surface markers using ﬂow cytometry.
The following monoclonal antibodies were used: ﬂuorescein
isothiocyanate (FITC)—labeled mAb speciﬁc for human
CD3, CD4, CD45RA; phycoerythrin (PE)—labeled mAb
speciﬁc for human CD25, CD28, CD45RO, CD56, CD62L,
CD69, CCR7, and TCR γ/δ; peridin chlorophyll protein
(PerCP)—labeled mAb speciﬁc for the human CD8 (Bec-
ton Dickinson (BD) Biosciences (San Jose, CA)). Surface
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a monoclonal antibody Fc-speciﬁc Cyanine-Cy5-conjugated
(Fc-Cy5) (Jackson ImmunoResearch, West Grove, PA) rec-
ognizing the IgG1-CHCH3 component of the CAR. Cells
were analyzed using a FACSCalibur ﬂow cytometer (BD
Biosciences). The human AML10 cells were analyzed for
leukemic markers before and after contact with CD33-
speciﬁc EBV-CTLs. The monoclonal antibodies used were
FITC—labeled mAb speciﬁc for human CD33, CD38,
CD123, CD13; PE—labeled mAb speciﬁc for human CD33,
CD34. All gates were set using appropriate isotype control
antibodies.
2.5. Expansion Rate Evaluation. After retroviral transduc-
tion, EBV-CTLs were rested in complete media without IL-
2 for 2 days. Cells were then washed, counted, and plated
at 1 × 106 per well of a 24-well plate at a ratio of 4:1
with autologous LCLs. Cocultures were performed in the
presence of low doses of rhIL-2 (20U/mL). Expansion rate
was assessed twice weekly by Trypan blue exclusion.
2.6. Determination of Speciﬁc Cytolysis by Chromium-Release
Assay. The in vitro cytolytic activity of CAR-expressing
EBV-CTLs was determined by 51Chromium-release assay.
Brieﬂy, EBV-CTLs were incubated for 4 hours with 5 ×
103 Na51CrO4 (51Cr, MP Biomedicals, Orangeburg, NY)—
labeled target cells (KG-1, autologous and allogeneic LCLs).
Eﬀector cells (unmodiﬁed EBV-CTLs and anti-CD33.CAR-
expressing EBV-CTLs) were harvested 7 and 28 days after
transduction, washed, and incubated in triplicate with their
51Cr labeled targets. To determine whether cytolysis was
restricted to MHC class I or CD33, target cells were incu-
bated with anti-human HLA-A,B,C (clone W6/32) (Dako,
Carpinteria, CA) or anti-CD33 (Chemicon, Temecula, CA,
USA) monoclonal antibodies at 20μg/mL for 30 minutes
at room temperature before the addition of eﬀector cells.
The percentage of speciﬁc cytolysis was calculated from the
release of 51Cr, using a Cobra II AutoGAMMA (Canberra
Packard Ltd, Pangbourne, Berks, UK). Data are reported as
mean of 51Cr release ± standard deviation (SD).
2.7. Determination of IFN-γ a n dG r a n z y m eBR e l e a s eb y
Eﬀector Cells Using the ELISpot Assay. Anti-CD33.CAR-
expressing EBV-CTLs were cocultured with irradiated autol-
ogous LCLs and K562 cell line in an enzyme-linked
immunospot (ELISpot) assay for IFN-γ and Granzyme B
(GrB) (BD Biosciences), according to the manufacturer’s
i n s t r u c t i o n s .T h es a m ee ﬀector cells (CAR-expressing EBV-
CTLs) stimulated with 0.1μg/mL phorbol myristate acetate
(PMA)/ionomycin (Sigma, St Louis, MI) were used as
internalpositivecontrol.Eﬀectorcells(1×105)werecultured
in duplicate with 2 × 105 of each speciﬁc target per well of
a 24-well plate. Blocking experiments were performed using
humananti-HLAIandanti-CD33monoclonalantibodies,as
described above, before the addition of eﬀectors cells. Spots
were developed according to the manufacturer’s instructions
and were enumerated using the Series 1 ImmunoSpot Image
Analyzer and software (Cellular Technologies, Cleveland,
OH).
2.8. Clonogenic Assay. Human bone marrow samples were
obtained from commercial sources. Human CD34+ bone
marrow cells were isolated using immunomagnetic beads
(Miltenyi Biotech, Auburn, CA), incubated for 4 hours with
unmodiﬁed or anti-CD33.CAR-expressing EBV-CTLs at an
E:T ratio of 1:1 and plated at 2 × 104 cells/dish in a
methylcellulose-based medium (MethoCult H4434; Stem-
Cell Technologies Inc., Vancouver, BC, Canada). After 10
days, for each modiﬁed EBV-CTLs population, granulo-
cyte monocytic colony-forming units (CFU-GMs), granulo-
cyte,erythroid,macrophage,megakaryocytecolony-forming
units (CFU-GEMMs), and erythroid burst-forming units
(BFU-Es) colonies were counted. Results are represented as
relative colony number compared with the control bone
marrowprogenitorCD34+ notexposedtoanyEBV-CTLs,set
to 100%. To conﬁrm the enumeration assays, colonies were
collected and characterized by ﬂow cytometry to analyze the
expression of a set of surface markers speciﬁc for each colony
type. The following antibodies were used: FITC—labeled
anti human CD33 CD38, PE—labeled anti human CD38,
CD54, CD71, and PerCP—labeled anti-human CD45RA,
CD38, CD34 (BD Biosciences). Marked cells were analyzed
using a FACSCalibur ﬂow cytometer (BD Biosciences).
2.9. Xenograft Mouse Model and Treatment. On day 0, 6-
week-old female NOD/SCID mice (Jackson Laboratory, Bar
Harbor, ME) were subcutaneously injected with 2 × 106
ﬀLuc+ AML10 cells. Beginning on day 5, tumor engraftment
was evaluated in vivo using biophotonic imaging. Mice with
growing tumors were divided into 4 treatment groups (8
mice/group)receivingweeklyintravenousinjectionsofsaline
serum, 5 × 106 unmodiﬁed EBV-CTLs, or anti-CD33.CAR-
expressing EBV-CTLs. Anesthetized mice were imaged using
a Xenogen IVIS 100 series system (Xenogen, Alameda, CA)
15 minutes after intraperitoneal injection of 4.29mg/mouse
of D-luciferin potassium salt solution (Xenogen). Photons
emitted from ﬀLuc+ AML10 xenografts were quantiﬁed
usingtheLivingImagesoftware(Xenogen).Bioluminescence
was measured as total photon ﬂux normalized for exposure
time and surface area and expressed in units of photons (p)
per second per cm2 per steradian (sr) as previously vali-
dated [4]. Tumor response was monitored weekly over the
treatment period. All animal experiments were performed
according to institutional guidelines.
2.10. Histology and Immunoﬂuorescence. Mice were euth-
anized 48 hours after the end of the treatment. Tumors
were ﬁxed in 10% formalin then embedded in paraﬃn.
Sections(5μm)wereusedforroutinehematoxylin/eosinhis-
tology and for immunoﬂuorescence. Immunohistochemical
detection of CD8+ EBV-CTLs and CD33 expression in the
AML10 tumors was performed after blocking nonspeciﬁc
binding with 10% normal goat serum in PBS for 30 minutes.
Tumor sections were then washed in PBS and incubated
with primary mAb (anti human CD8 or anti human CD33,
Abcam, Cambridge, MA) at a 1:25 dilution for 1 hour
at room temperature. Sections were then washed in PBS,
incubated with the secondary antibody (FITC goat anti-
mouse, Abcam) at a 1:100 dilution. After further washes,4 Advances in Hematology
slides were counterstained with Hoechst solution (Sigma)
during 10 minutes at 37◦C, washed and mounted in
Vectashield medium (Dako). Tissue sections were examined
with a Zeiss Axiophot ﬂuorescence microscope (Carl Zeiss
L t d . ,H e r t f o r d s h i r e ,U K ) .
2.11. Statistical Analysis. All in vitro data are presented as
mean ± standard deviation (SD). Student’s t-test was used
to determine statistical signiﬁcance of diﬀerences between
samples, and P value ≤ 0.05 was considered as indicating a
signiﬁcant diﬀerence. For the bioluminescent experiments,
intensity signals were log-transformed and summarized
using mean ± SD at baseline and multiple subsequent time
points for each group of mice. Changes in intensity of
signal from baseline at each time point were calculated and
compared using paired t tests or Wilcoxon signed rank tests
(Statview 5.0, SAS Institute Inc.) [4].
3. Results
3.1. Transduced EBV-CTLs Stably Express the Anti-
CD33.CAR, While Maintaining Their Native EBV-CTLs
Characteristics. EBV-CTLs from 6 EBV-seropositive donors
were generated and retrovirally transduced to express the
anti-CD33.CAR. The genetically modiﬁed EBV-CTLs were
evaluated for expression of the CAR by ﬂow cytometry
using a mAb speciﬁc for the CH2CH3 domain. Genetically
modiﬁed EBV-CTLs expressed the CAR (Figure 1(a))7d a y s
after transduction, with a mean percentage of 35% ± 4%
(n = 6) of positive cells. The transgene expression was still
detected approximately at the same levels 1 month after
transduction (mean percentage of CAR-expressing cells,
30% ± 5%). At this time point, the expression of CD4, CD8,
CD3, CD56, CD25, CD45RA, and CD62L was unchanged
in genetically modiﬁed EBV-CTLs compared to controls
(Figure 1(b)). The expansion rate of anti-CD33.CAR-
EBV-CTLs did not diﬀer signiﬁcantly upon coculture for
21 days with CD33−EBV+ autologous LCLs compared to
unmodiﬁed EBV-CTLs (Figure 1(c)).
3.2. Anti-CD33.CAR-Transduced EBV-CTLs Are Functionally
Bispeciﬁc. We then investigated the ability of genetically
modiﬁed CD33-speciﬁc EBV-CTLs to be activated and
exert eﬀector functions through their endogenous TCR and
the transduced CD33-speciﬁc CAR. Four-hour chromium-
release assays showed that the anti-CD33.CAR-transduced
EBV-CTLs were able to kill autologous LCLs with the same
eﬃciency as unmodiﬁed EBV-CTLs (mean lysis at 50:1
eﬀector:target ratio of 40% ± 7%; n = 6, compared to a
mean lysis of 48% ± 7%; n = 6 of untransduced EBV-CTLs)
(Figure 2(a)). Incubation of autologous LCLs with MHC
class I showed that MHC class I, as expected, was the major
restriction element for the native antigen receptor function
in both nontransduced and gene-modiﬁed EBV-CTLs, with
am e a nl y s i sa t5 0 : 1e ﬀector:target ratio of 12% ± 2%
and 11% ± 4%, respectively, for unmanipulated and anti-
CD33.CAR-transduced EBV-CTLs (Figure 2(a), P ≤ 0.05).
Inadditionanti-CD33.CAR-expressingEBV-CTLscouldlyse
eﬃciently the CD33+ expressing KG-1 cell line (mean lysis at
50:1 eﬀector:target ratio of 39% ± 6%; n = 6c o m p a r e dt o
am e a nl y s i so f5 %± 3% of untransduced EBV-CTLs; n = 6;
P ≤ 0.05). Preincubation of CD33+ KG-1 target cells with a
CD33-blocking MoAb resulted in a signiﬁcant inhibition of
lysis (up to 40%) by CD33-speciﬁc EBV-CTLs, with a mean
lysis at 50:1 eﬀector:target ratio of 15%±2% (Figure 2(b)).
The ability of CD33-speciﬁc EBV-CTLs to secrete cy-
tokines in response to both EBV+ and CD33+ targets was
investigated by ELISpot assay after culturing target cells
either with unmodiﬁed or genetically-modiﬁed EBV-CTLs.
Levels of Th1 (IFN-γ) and Tc (GrB) cytokines released
by modiﬁed and unmodiﬁed EBV-CTLs in response to
EBV+ targets were almost similar (mean spot forming cells-
SFC-/105 cells of 380 ± 12 and 331 ± 19, respectively, for
anti-CD33.CAR-transduced EBV-CTLs and unmanipulated
EBV-CTLs for IFN-γ,( Figure 3(a), left panel) and mean
SFC/105 cells of 220 ± 29 and 254 ± 22, respectively, for
anti-CD33.CAR and unmanipulated EBV-CTLs for GrB,
(Figure 3(b), left panel). This response to EBV+ cells was
mediated by the native TCR as demonstrated by blocking
class I MHC antigens on target cells which signiﬁcantly
reduced the cytokine release by 40 to 50% (Figures 3(a) and
3(b), left panel). No production of cytokines was detectable
after exposure of unmodiﬁed EBV-CTLs to CD33+ targets,
whereas IFN-γ and GrB cytokine production was seen in
response to stimulation of anti-CD33.CAR-transduced EBV-
CTLs by CD33+ cells (mean SFC/105 cells of 190 ± 16 for
IFN-γ and mean SFC/105 cells of 241 ± 9 for GrB) (Figures
3(a) and 3(b), right panel). This activity was mediated by the
chimeric receptor pathway since CD33 MoAb signiﬁcantly
blocked IFN-γ and GrB secretion in a range of 40 to 50%
(Figures 3(a) and 3(b), right panel).
3.3. Anti-CD33.CAR-Transduced EBV-CTLs Have a Myeloab-
lative Activity In Vitro, But the Colony-Forming Capacity Is
Maintained. Exposure of CD34+ bone marrow progenitor
cells to unmodiﬁed EBV-CTLs was associated with a mean
reduction in colony number of 20% for CFU-GM and 38%
for CFU-GEMM compared to the control (Figure 4(a)),
whereas anti-CD33.CAR-EBV-CTLs signiﬁcantly reduced
the CFU counts by 58% to 75% compared to the control
(P ≤ 0.005) (Figure 4(a)). BFU-E subpopulation, which
does not express CD33, was not aﬀected by the activity of
anti-CD33.CAR-transduced EBV-CTLs. These results were
conﬁrmed by ﬂow cytometry analysis, which showed a
signiﬁcant decrease (P ≤ 0.05) in the expression of cell
surface markers of CFU-GEMM and CFU-GM, with BFU-E
being not aﬀected (Figure 4(b)). Overall, our results indicate
that despite anti-CD33.CAR-transduced EBV-CTLs had a
c y t o l y t i ca c t i o no nC D 3 4 + progenitor cells, those remained
capable to generate normal progeny.
3.4. Anti-AML Eﬀect of Anti-CD33.CAR-Transduced EBV-
CTLs In Vivo. When we analyzed the in vivo antitumor
activity of anti-CD33.CAR genetically modiﬁed EBV-CTLsAdvances in Hematology 5
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Figure 1: EBV-CTLs could be stably transduced with the anti-CD33.CAR without alteration in their native immunophenotype and
expansion rate. (a) The expression of the anti-CD33.CAR on the surface of EBV-CTLs was evaluated by ﬂow cytometry with a Cy5-
conjugated-mAb speciﬁc for the CH2CH3 domain of the CAR after 7 days of culture. A representative plot of EBV-CTLs transduction
after 7 days of culture is shown. (b) The expression of CD4, CD8, CD3 along with CD56, CD4, and CD8 along with CD25, CD4, and
CD8 along with CD45RA, CD4, and CD8 along with CD62L on the surface of EBV-CTLs was evaluated after 30 days of culture by ﬂow
cytometry. (c) Proliferation of anti-CD33.CAR-transduced EBV-CTLs compared to unmanipulated EBV-CTLs was evaluated by cell count
with Trypan blue exclusion after weekly stimulations at 4:1 ratio with either irradiated autologous LCLs. Cells were cultured with low-dose
rhIL-2 (20U/mL). Data shown are mean ± SD of 6 separate experiments.
in AML10-bearing mice, we observed that, compared to
untreated mice or to mice receiving EBV-CTLs, anti-
CD33.CAR-expressing EBV-CTLs reduced tumor progres-
sion (tumor inhibition rate 43% versus 12%, P ≤ 0.05,
Wilcoxon rank sum test) (Figures 5(a) and 5(b)).
Immunohistochemistry performed on tumors analyzed
48 hours after i.v. administration of EBV-CTLs seems
to indicate that anti-CD33.CAR-EBV-CTLs were able to
inﬁltrate the tumor (Figure 6). Genetically modiﬁed T cells
were found at the periphery of the tumor in the vicinity of
vessels, isolated or forming cluster (arrowheads or arrows,
resp.).
4. Discussion
Our results show that the expression of CD33 chimeric
receptor in EBV-speciﬁc CTLs, while does not aﬀect their
phenotype and does not interfere with their ability to
proliferate or to respond to autologous EBV-infected targets,
renders them capable to speciﬁcally lyse CD33+ target cells
andreleaseTh1andTccytokinesuponencounterwithtarget
cells, even though the low average transduction eﬃciency.
In order to further improve this percentage and possibly
augmenting CAR+ T-cell response to its speciﬁc target,
we might concentrate anti-CD33.CAR-speciﬁc retroviral6 Advances in Hematology
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Figure 2: Anti-CD33.CAR-transduced EBV-CTLs eﬃciently killed autologous LCLs and CD33+ KG-1 cells. Cytotoxicity of unmanipulated
EBV-CTLs and anti-CD33.CAR-transduced EBV-CTLs was evaluated by a standard 4-hour 51Chromium-release assay after 7 days of culture
ateﬀector:target(E:T)ratiosof50:1,25:1,10:1and5:1againstautologousLCLs(a)andCD33+ KG-1cellline(b).Toassessthespeciﬁcity
of either HLA-I-mediated and CAR-induced killing, target cells were preincubated with anti-human HLA-I (a) antibodies or an anti-human
CD33 monoclonal antibody (b) before the addition of the eﬀector cells. Data shown are mean ± SD of 6 separate experiments;
∗P ≤ 0.05.
supernatant administration by increasing the Multiplicity of
Infection (MOI)/cells ratio. However, more eﬀorts will be
needed to ﬁnd new regulatory elements such as insulators,
tissue-speciﬁc promoters, or ribosome-binding sites, alone
or in combination, to be included in the speciﬁc transgene
plasmid in order to increase transcription eﬃciency in T
cells. This will certainly be accompanied by a decreased of
the in vitro E:T ratio, increasing the killing capacity of the
transduced T cells, phenomenon that we can predict would
also have an impact in the T-cell eﬃciency after clinical
infusion. These results conﬁrm that the engagement of the
chimeric receptor by tumor antigen initiates signalling to
the T-cell nucleus and induces eﬀector functions, including
cytokine secretion and speciﬁc lysis of antigen-expressing
tumor cells in vitro. T-cell retargeting operates in an MHC
unrestricted manner to attack the tumor, whereas it retains
MHC-restricted speciﬁcity for the endogenous TCR. When
weanalyzedtheinvivoactivityofanti-CD33.CARgenetically
modiﬁed EBV-CTLs in a mouse model of AML, we observed
that intravenous administration of CD33-redirected EBV-
CTLs in AML-bearing mice can exert a signiﬁcant albeit
partial antileukemic activity. The incomplete antitumoral
eﬀect exerted by anti-CD33.CAR-transduced EBV-CTLs
might be related to their limited persistence in vivo in this
animal model, an expected outcome given that CTLs were
injected intravenously without concomitant administration
of recombinant human IL-2 and the lack of chronic EBV
stimulation in NOD/SCID mice. Indeed, studies reporting
complete regression of tumor in mice were performed
by intratumoral injection of T cells expressing chimeric
receptorsand/oradditionofintravenousIL-2,orvaccination
with autologous LCLs [3, 21, 22], which may have allowed
f o ri m p r o v e dT - c e l ls u r v i v a la n din vivo expansion. Of note,
despite the lack of cytokine addition or EBV stimulation,
anti-CD33.CAR-transduced EBV-CTLs were able to home
andinﬁltratethetumor,wheretheyexertedasigniﬁcantanti-
tumor activity. In addition, we observed that the repeated
administrations of anti-CD33.CAR-transduced EBV-CTLsAdvances in Hematology 7
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Figure 3: Anti-CD33.CAR-transduced EBV-CTLs released substantial levels of IFN-γ and Granzyme B when stimulated with either
autologous LCLs and CD33+ KG-1 cells. Release of IFN-γ (a) and Granzyme B (b) from unmanipulated or anti-CD33.CAR-transduced
EBV-CTLs was evaluated by ELISpot assays after stimulation with either irradiated autologous LCLs or irradiated KG-1 cells at 1:2 ratio.
To assess the speciﬁcity of either HLA-I-mediated and CAR-induced cytokine release target cells were preincubated with anti-human HLA-I
antibodies or an anti-human CD33 monoclonal antibody before the addition of the eﬀector cells. Data shown are mean ± SD of 6 separate
experiments;
∗P ≤ 0.05;
∗∗P ≤ 0.005.
did not result in the selection of CD33-negative tumor
clones, that would be resistant to our therapeutic approach.
Even though results form a recent phase I clinical
trial with EBV-CTLs genetically modiﬁed with a chimeric
receptor speciﬁc for the GD2 antigen carrying just the ζ
intracellular domain clearly indicate that these cells are
very eﬀective in terms of anti-tumor activity and that their
eﬃcacyissustainedbytheircapacitytopersistuponinfusion
[8], other strategies can be exploited to improve their
persistence. One possibility is represented by coexpression of
genes coding for homeostatic cytokines, such as IL-15 [23],
or the vaccination with LCLs, to promote the physiologic
restimulation of EBV-CTLs trough their native TCR, or
lymphodepletion prior to the EBV-CTLs infusion, to remove
T-suppressor cells and recreate a more favourable cytokines
milieu [24, 25]. In addition, the current availability of new
immunodeﬁcient models (e.g., NOD/SCID/γc−/−)[ 26, 27]
might help in better characterizing the in vivo anti-tumor
activity of these cells in preclinical settings. Indeed, when
moving to the clinical setting, this kind of cell therapy
approach could be further improved by various strategies,
as already exploited for other types of tumor: patients could
receive preventively a short schedule of chemotherapy to
decrease the burden of disease, and, immediately before the
injection, a lymphodepletive ﬂudarabin-based scheme could
be also added to favour the expansion of cells after infusion
and the depletion of regulatory T cells. Moreover, addition
of systemic administration of clinical-grade IL-2, IL-15, or
IL-7 could be of further help to improve cell expansion and
survival.
Taken together our data highlight that CD33+AML
adoptive immunotherapy using CD33-speciﬁc EBV-CTLs
mightbeanalternativestrategytoanantibody-basedtherapy
such as gemtuzumab ozogamicin. This is particularly rele-
vant in light of the frequently and severe reported hepatic
toxicity related to the addition of a toxic compound to the8 Advances in Hematology
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Figure 4: Cytotoxicity of anti-CD33.CAR-transduced EBV-CTLs
against normal myeloid progenitors. (a) Unmanipulated or anti-
CD33.CAR-transduced EBV-CTLs were incubated with bone-
marrow-derivedCD34+ progenitorsatE:Tratioof1:1for4hours.
Cells were then seeded in methylcellulose-based medium and after
10 days CFU-GM, CFU-GEMM, and BFU-E were counted. Data
shown are mean ± SD of 6 independent experiments. (b) Colonies
were collected and characterized by ﬂow cytometry to assess the
expression of surface markers speciﬁc for each colony type. Data
shown are mean ± SD of 6 independent experiments.
CD33 targeting and subsequent calicheamicin accumulation
and/or unwanted release and toxicity to normal cells sur-
rounding CD33+ tumor cells. Another advantage of CD33-
speciﬁc EBV-CTLs over gemtuzumab ozogamicin is their
independence from the MDR1 pathway, a known factor of
chemoresistance to calicheamicin. Moreover, in immuno-
compromised patients, the administration of chimeric T
cells endowed per se with anti-tumoral activity may prove
more eﬀective than the use of monoclonal antibodies, whose
eﬃcacyisimpairedbydysfunctionalorabsentimmuneeﬀec-
tors. Finally, in patients with CD33+ AML, leukemic stem
cells are considered a major cause of relapse based on their
repopulating capacity and thus represent a critical target
for AML-speciﬁc therapies [28, 29]. Since AML stem cells
reside within the CD34+CD38−CD33+ compartment of the
leukemic clone [12, 30], eradication of this subpopulation
by targeting CD33 is predicted to give therapeutic beneﬁt to
treated patients.
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Figure 5: In vivo activity of anti-CD33.CAR-transduced EBV-
CTLs against AML10. NOD/SCID mice were subcutaneously
injected with ﬀLUC+AML10 cells, and after 5 days mice were
weekly intravenously injected with either PBS, unmanipulated or
anti-CD33.CAR-transduced EBV-CTLs. (a) Tumor volume was
monitored weekly after D-luciferin injection using a Living Image
software and was quantiﬁed as total photon ﬂux normalized for
exposure time and surface area and expressed in units of photons
(p) per second per cm2 per steradian (sr). Data shown are mean
± SD of 8 mice/group;
∗P ≤ 0.05. (b) Intensity signals were log-
transformed and summarized using mean ± SD at baseline and
multiplesubsequent timepoints for each group of mice. Changes in
intensity of signal from baseline at each time point were calculated.
On the other side, concerning the potential toxicity on
the normal myeloid compartment, our results indicate that,
at least in vitro, anti-CD33.CAR-transduced-EBV-CTLs did
not irreversibly impair the functions of CD33+ hematopoi-
etic progenitors, as conﬁrmed in a recently published paper
using CIK cells expressing anti-CD33.CAR [18]. This might
be partially explained by the fact that not all normal human
hematopoietic progenitors express CD33 on their surface
[12]. We are now in the process of corroborating these data
inamurineNOD/SCID/γc−/− modelreconstitutedwithnor-
malhematopoieticprogenitors.Anyhow,wearewellawareof
the potential risks in humans, and, certainly, ﬁrst trials willAdvances in Hematology 9
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Figure 6: Inﬁltration of tumors by EBV-CTLs. Forty-eight hours
after i.v. administration of EBV-CTLs, tumors were resected, ﬁxed
in 10% formalin solution, and embedded in paraﬃn. CD8+ EBV-
CTLs were detected by immunohistochemistry using an anti-CD8
antibody and reported in (a) unmodiﬁed EBV-CTLs, (b) CD33-
EBV-CTLs.GeneticallymodiﬁedTcellswerefoundattheperiphery
of the tumor in the vicinity of vessels (indicated as “V”), isolated or
forming cluster (arrowheads or arrows, resp.).
necessarily require a dose-escalation scheme, starting form
very low doses and progressively increasing towards higher
numbers of infused cells. Moreover, a construct containing a
suicide gene would be highly desirable (as discussed at the
end), so that, in case of unwanted or severe toxicity, cells
can be rapidly killed. More selective antigens for the AML
leukaemia stem cell are under investigation (such as CD123
or CD44 [28, 29]), in case of limiting myeloid toxicity related
to the CD33 targeting.
Following ongoing clinical applications of chimeric T
cells in B-cell malignancies [31, 32], the development
of CD33-targeting approaches using chimeric EBV-speciﬁc
T cells includes the generation of anti-CD33 chimeric
EBV-CTLs from the stem cell donor and the subsequent
administration to patients with early relapse following
allogeneic bone marrow transplantation, either preemp-
tively or prophylactically. In such a circumstance, since the
toxicity towards the normal myeloid compartment is still
unknown, an approach to increase the safety of modiﬁed
anti-CD33.CARcellswouldbedesirable,suchastheaddition
o fas u i c i d eg e n e ,a sd e s c r i b e db yo u rg r o u pe l s e w h e r e[ 18].
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